Health X Platform Limited has resolved a significant legal dispute with the tax authorities, receiving a final order from the Customs, Excise and Service Tax Appellate Tribunal (CESTAT) that fully favors the company. The tribunal allowed the appeal filed against the Commissioner of Service Tax, Kolkata, setting aside a demand for ₹65,19,360 related to alleged non-payment of service tax, education cess, and higher education cess under the Finance Act, 1994. This resolution eliminates any potential financial liability or penalty exposure for Health X Platform, providing clarity on a matter that had been pending since 2014.

The litigation was initiated on June 23, 2014, when the company filed an appeal against an order passed by the Commissioner of Service Tax. The dispute centered on allegations of contravention of the Finance Act, 1994 provisions. Over the years, the case saw multiple hearing dates, including rescheduled sessions in January, March, May, June, July, September, and December of 2025, as well as March 2026. The most recent hearing prior to the verdict was scheduled for June 15, 2026, but the authority pronounced its final decision earlier.

The CESTAT delivered its final order on July 30, 2026, which the company received on August 3, 2026. In its ruling, the authority held that the impugned demand of service tax was not sustainable. Consequently, the tribunal set aside the entire demand and explicitly stated that no penalties are imposable on the company. The appeal was allowed with consequential relief, if any, ensuring that Health X Platform faces no adverse financial consequences from this specific litigation.

This update was disclosed by the company to the Bombay Stock Exchange and the National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Regulations. The disclosure aligns with the requirements of sub-para 8 of para B of Part A of Schedule III, read with Annexure 18 of the Master Circular dated November 11, 2024, regarding ongoing tax litigations and disputes.

Litigation Timeline and Details

What the Numbers Show

The resolution of this case is entirely positive for Health X Platform’s balance sheet. With the CESTAT ruling that the demand is not sustainable, the company avoids an immediate cash outflow of ₹65,19,360. More importantly, the explicit statement that "no penalties are imposable" removes the risk of additional financial burdens that often accompany tax disputes. Since there is no material financial impact, this outcome does not alter the company’s current fiscal projections but does improve its legal risk profile by closing a long-standing chapter of regulatory uncertainty.

Health X Platform reported a 22% year-on-year increase in revenue from operations to ₹356 crore for the quarter ended March 31, 2026, driven by sustained growth across its B2B and B2C verticals. The company significantly narrowed its EBITDA loss to ₹20 crore, an improvement of 29% compared to the corresponding quarter of the previous year, while EBITDA margins improved to negative 5.5% from negative 10.3% in Q4 FY25. Gross profit for the quarter rose 45% year-on-year to ₹26.5 crore, with gross margins expanding to 7.3% from 5.9% in the prior year, attributed to a better product mix and stronger procurement efficiency.

For the full financial year FY26, the company recorded revenue from operations of ₹1,283 crore, reflecting an 18% year-on-year growth. Gross profit increased by 36.5% to ₹96.5 crore, and gross margins improved by 100 basis points to 7.5%. EBITDA losses for the year reduced substantially from ₹79 crore in FY25 to ₹65 crore in FY26. The company reported a net loss of ₹1.4 crore for FY26, a sharp turnaround from the net loss of ₹133 crore in the previous year, supported by operational efficiency and disciplined cost management.

Strategic Initiatives and Future Outlook

The management highlighted that the B2B platform, Retailer Shakti, is now operating almost at breakeven and is contribution-margin positive, covering its corporate costs. The B2C platform, SastaSundar, remains capital efficient with a working capital cycle of 18 days. The company maintained a working capital efficiency of approximately 5% of annual sales and held a cash balance of around ₹30 crore, excluding treasury investments.

Looking ahead, the company targets ₹6,000 crore of revenue by Financial Year 2030, comprising ₹4,000 crore from B2B operations and ₹2,000 crore from B2C operations. To support this growth, the company plans a capital expenditure of ₹234 crore to expand warehousing capacity in Udaipur, Lucknow, Patna, Guwahati, and West Bengal. The management also introduced JITO, a private-label generic medicine category, aiming to offer medicines up to 60% cheaper than branded alternatives, with initial monthly sales around ₹30 lakh.

Corporate Restructuring

The Board of Directors has approved a scheme of simplification of corporate structure, wherein the Finance Division will be demerged and listed separately as Microsec Resources Ltd. Existing shareholders of Health X Platform will be allotted one equity share of Microsec Resources for every three shares held. Microsec Resources will hold an asset base of approximately ₹140 crore, comprising ₹100 crore in financial assets and ₹40 crore in real estate, while the majority of the treasury, around ₹400 crore, will remain with the operating healthcare business.